Mabylon AG Secures CHF 1.3 Million for ALS and Inflammatory Research
Mabylon AG Secures Critical Funding for Innovative Therapies
Mabylon AG, a prominent player in the biotechnology sector specializing in human-derived antibodies, recently announced its remarkable achievement of securing three research grants totaling over CHF 1.3 million. This funding has been designated for its programs focused on amyotrophic lateral sclerosis (ALS) and inflammasome-targeting therapies. These developments reveal a commitment to pushing the boundaries of medical research and treatment.
Focus on Amyotrophic Lateral Sclerosis
The lucrative grants include significant contributions from entities like the Innosuisse Swiss Innovation Agency, Target ALS, and the ALS Association. The funding is focused specifically on advancing the development of TDP-43 intrabodies, which are designed to restore the normal functions of TDP-43 in ALS patients. There is a critical need for effective treatments as TDP-43 aggregates are instrumental in the progression of ALS.
The Importance of TDP-43
TDP-43 has been recognized as a pivotal target in the fight against ALS, affecting both familial and sporadic forms of the disease. Kuldip Dave, Ph.D., Senior Vice President of Research at the ALS Association, expressed optimism regarding the funding's impact on preclinical development efforts, indicating that making rapid progress in treatment options is paramount in managing ALS.
Advances in Inflammatory Bowel Disease Treatment
Aside from its ALS initiatives, Mabylon is also channeling CHF 0.8 million from Innosuisse into its ongoing MY012 program. This innovative antiviral therapy focuses on treating inflammatory bowel disease (IBD) and is designed to enhance both safety and efficacy in patient treatment.
Innovative Approaches to Safe Treatments
Mabylon’s strategy involves identifying naturally occurring antibodies from extensive patient populations or immunized animals. This groundbreaking approach sets the foundation for uncovering promising antibody candidates in ALS and IBD. According to Niccolò Pengo, PhD, Mabylon’s Chief Scientific Officer (CSO), these grants affirm the validity of their research and underscore the therapeutic potential of their discoveries. The funding provides an opportunity to expedite their research programs and assist in future fundraising efforts.
Vision for the Future
Alcide Barberis, PhD, CEO of Mabylon, expressed heartfelt gratitude for the grants, which will support their efforts to reach preclinical proof-of-concept. The goal is to foster partnerships with biopharmaceutical companies or potentially launch a dedicated spinoff to facilitate investments. With a keen focus on developing their innovative anti-allergen antibody candidates, the company is poised for growth and expansion.
Recent Collaborations and Developments
In recent months, Mabylon has made significant strides in its anti-allergen therapies, particularly with a multi-specific anti-allergen antibody currently undergoing Investigative New Drug (IND) studies. This project aims to deliver critical treatments for peanut allergies. Notably, Mabylon has partnered with Pfizer via the Pfizer Ignite program to propel its allergy treatment initiatives forward.
About Mabylon AG
Mabylon AG is a Swiss biotechnology firm dedicated to leveraging the therapeutic capabilities of naturally occurring human antibodies to address allergies, neurodegenerative diseases, and inflammatory conditions. By focusing on antibodies derived from allergic patients, Mabylon's research is enhancing the understanding of allergenic epitopes and their implications in disease progression.
Frequently Asked Questions
What grants has Mabylon AG received?
Mabylon AG has received over CHF 1.3 million in research grants focused on ALS and inflammatory diseases.
How is the funding benefiting ALS research?
The funding is allocated towards developing TDP-43 intrabodies, aimed at restoring normal TDP-43 function in ALS patients.
What is the MY012 program?
The MY012 program targets inflammatory bowel disease, utilizing a proprietary antibody therapy designed for enhanced safety and effectiveness.
What collaborations does Mabylon have?
Mabylon has entered a collaboration with Pfizer for its allergy program through the Pfizer Ignite initiative.
What is Mabylon AG's primary focus?
Mabylon AG focuses on harnessing naturally occurring human antibodies to innovate treatments for allergies, neurodegenerative diseases, and inflammatory conditions.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.